New hives drug put to the test in massive Real-World study
NCT ID NCT07358364
Summary
This study aims to see how well a new drug called remibrutinib works for controlling chronic spontaneous urticaria (CSU), or long-lasting hives, in everyday medical practice. It will follow about 3,280 adults whose doctors have already decided to either increase their current allergy medicine dose or switch them to remibrutinib. Researchers will track patients for two years to collect real-world data on how well the drug controls hives, its safety, and its impact on quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Cleaver Dermatology
RECRUITINGKirksville, Missouri, 63501, United States
Conditions
Explore the condition pages connected to this study.